U
CRL icon

UBS’s Charles River Laboratories CRL Stock Holding History

UBS’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-900
Closed -$37K – 10399
2013
Q2 		$37K Buy
+900
New +$38.6K ﹤0.01% 7122

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's CRL Position: Q3 2014 in Review

UBS reduced its Charles River Laboratories (CRL) stake by 68% in Q3 2014, selling an estimated $2.48M and leaving 20,402 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3395.

UBS first reported a position in CRL in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.41M in Q2 2014. 255 funds tracked by Wall St. Rank hold CRL as of Q3 2014.

  • UBS held 20,402 shares of Charles River Laboratories worth $1.22M as of Q3 2014.
  • UBS sold 43,294 Charles River Laboratories shares in Q3 2014, an estimated $2.48M.
  • Charles River Laboratories made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3395 holding.
  • UBS first reported a position in Charles River Laboratories in Q2 2013 and has held it in 6 quarters since.
  • UBS's Charles River Laboratories position peaked at $3.41M in Q2 2014.
  • 255 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.